C

Central Pharmaceutical JSC No3
VN:DP3

Watchlist Manager
Central Pharmaceutical JSC No3
VN:DP3
Watchlist
Price: 53 000 VND -0.75%
Market Cap: 1.1T VND

Wall Street
Price Targets

DP3 Price Targets Summary
Central Pharmaceutical JSC No3

Wall Street analysts forecast DP3 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DP3 is 64 770 VND with a low forecast of 64 135 VND and a high forecast of 66 675 VND.

Lowest
Price Target
64 135 VND
21% Upside
Average
Price Target
64 770 VND
22% Upside
Highest
Price Target
66 675 VND
26% Upside
Central Pharmaceutical JSC No3 Competitors:
Price Targets
KLBF
Kalbe Farma Tbk PT
11% Upside
SUPRIYA
Supriya Lifescience Ltd
19% Upside
300363
Porton Pharma Solutions Ltd
13% Upside
GLENMARK
Glenmark Pharmaceuticals Ltd
24% Downside
GS71
GSK plc
21% Upside
MANKIND
Mankind Pharma Ltd
4% Upside
IPN
Ipsen SA
22% Upside
300401
Zhejiang Garden Bio-chemical High-tech Co Ltd
17% Upside

Revenue
Forecast

Revenue Estimate
Central Pharmaceutical JSC No3

For the last 8 years the compound annual growth rate for Central Pharmaceutical JSC No3's revenue is 7%. The projected CAGR for the next 2 years is -97%.

7%
Past Growth
-97%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Central Pharmaceutical JSC No3

Operating Income forecast
is not available for
Central Pharmaceutical JSC No3

Net Income
Forecast

Net Income Estimate
Central Pharmaceutical JSC No3

Net Income forecast
is not available for
Central Pharmaceutical JSC No3
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DP3's stock price target?
Price Target
64 770 VND

According to Wall Street analysts, the average 1-year price target for DP3 is 64 770 VND with a low forecast of 64 135 VND and a high forecast of 66 675 VND.

What is Central Pharmaceutical JSC No3's Revenue forecast?
Projected CAGR
-97%

For the last 8 years the compound annual growth rate for Central Pharmaceutical JSC No3's revenue is 7%. The projected CAGR for the next 2 years is -97%.

Back to Top